Sales increased for the quarter 8% to $73 million, but unfortunately that came in at the low end of the guidance. And that growth is after the first quarter's disastrous $68 million performance. Losses decreased to $0.45 sequentially, but the company acknowledged that it won't hit its guidance target for year-over-year annual growth and refused to give additional guidance.
In this video, health-care analyst David Williamson discusses these results and key conference-call takeaways for investors in Dendreon, why they should be concerned about increasing competition, and why time is not on their side.
The Motley Fool recommends Exelixis and Johnson & Johnson and owns shares of Dendreon, Exelixis, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.